Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells 11,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX – Get Rating) CEO Grant Pickering sold 11,000 shares of the firm’s stock in a transaction on Monday, April 18th. The stock was sold at an average price of $23.98, for a total value of $263,780.00. Following the completion of the transaction, the chief executive officer now directly owns 703,894 shares in the company, valued at $16,879,378.12. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Grant Pickering also recently made the following trade(s):

• On Monday, March 21st, Grant Pickering sold 14,288 shares of Vaxcyte stock. The stock was sold at an average price of $24.94, for a total value of $356,342.72.

PCVX stock traded up $0.02 during trading on Wednesday, reaching $23.27. The company’s stock had a trading volume of 242,783 shares, compared to its average volume of 306,660. Vaxcyte, Inc. has a 1 year low of $15.51 and a 1 year high of $27.44. The firm has a market cap of $1.31 billion, a P/E ratio of -12.11 and a beta of 0.53. The company has a fifty day moving average price of $23.67.

Vaxcyte (NASDAQ:PCVX – Get Rating) last issued its quarterly earnings results on Monday, February 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.08). Analysts anticipate that Vaxcyte, Inc. will post -2.62 earnings per share for the current fiscal year.

A number of equities analysts recently commented on PCVX shares. Zacks Investment Research cut Vaxcyte from a “buy” rating to a “hold” rating in a report on Wednesday, March 2nd. Needham & Company LLC reiterated a “buy” rating and issued a $52.00 price target on shares of Vaxcyte in a research note on Thursday, February 24th.

Several institutional investors have recently modified their holdings of the company. Royal Bank of Canada grew its position in shares of Vaxcyte by 16.7% during the second quarter. Royal Bank of Canada now owns 2,922 shares of the company’s stock valued at $66,000 after purchasing an additional 418 shares in the last quarter. Swiss National Bank grew its position in shares of Vaxcyte by 2.2% during the fourth quarter. Swiss National Bank now owns 45,900 shares of the company’s stock valued at $1,092,000 after purchasing an additional 1,000 shares in the last quarter. California State Teachers Retirement System grew its position in shares of Vaxcyte by 3.2% during the fourth quarter. California State Teachers Retirement System now owns 39,465 shares of the company’s stock valued at $939,000 after purchasing an additional 1,227 shares in the last quarter. Deutsche Bank AG grew its position in shares of Vaxcyte by 4.8% during the fourth quarter. Deutsche Bank AG now owns 30,044 shares of the company’s stock valued at $714,000 after purchasing an additional 1,368 shares in the last quarter. Finally, Ensign Peak Advisors Inc purchased a new position in Vaxcyte in the fourth quarter worth about $34,000. Hedge funds and other institutional investors own 89.74% of the company’s stock.

Vaxcyte Company Profile (Get Rating)

Vaxcyte, Inc, a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis.

See Also